CoChat

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

Open access
Yamashita, Shizuya, Masuda, Daisaku, Matsuzawa, Yuji · 2020 · Current Atherosclerosis Reports

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index; 12 of the 168 sources its claims cite were checked for support.

Abstract

Purpose of Review: Reduction of serum low-density lipoprotein cholesterol (LDL-C) levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has been shown to significantly reduce cardiovascular events risk. However, fasting and postprandial hypertriglyceridemia as well as reduced high-density lipoprotein cholesterol (HDL-C) remain as residual risk factors of atherosclerotic cardiovascular diseases (ASCVD). To treat patients with hypertriglyceridemia and/or low HDL-C, drugs such as fibrates, nicotinic acids, and n-3 polyunsaturated fatty acids have been used. However, fibrates were demonstrated to cause side effects such as liver dysfunction and increase in creatinine levels, and thus large-scale clinical trials of fibrates have shown negative results for prevention of ASCVD. The failure could be attributed to their low selectivity and potency for binding to peroxisome proliferator-activated receptor (PPAR) α. To resolve these issues, the concept of selective PPARα modulator (SPPARMα) with a superior balance of efficacy and safety has been proposed and pemafibrate (K-877) has been developed. Recent Findings: Pemafibrate, one of SPPARMsα, was synthesized by Kowa Company, Ltd. for better efficiency and safety. Clinical trials in Japan have established the superiority of pemafibrate on effects on serum triglycerides (TG) reduction and HDL-C elevation as well safety. Although available fibrates showed worsening of liver and kidney function test values, pemafibrate indicated improved liver function test values and was less likely to increase serum creatinine or decrease estimated glomerular filtration rate (eGFR). Very few drug-drug interactions were observed even when used concomitantly with statins. Furthermore, pemafibrate is metabolized in the liver and excreted into the bile, while many of available fibrates are mainly excreted from the kidney. Therefore, pemafibrate can be used safely even in patients with impaired renal function since there is no significant increase in its blood concentration. A large-scale trial of pemafibrate, PROMINENT, for dyslipidemic patients with type 2 diabetes is ongoing. Summary: Pemafibrate is one of novel SPPARMsα and has superior benefit-risk balance compared to conventional fibrates and can be applicable for patients for whom the usage of existing fibrates is difficult such as those who are taking statins or patients with renal dysfunction. In the current review, all the recent data on pemafibrate will be summarized.

Overview

CoChat Summary

TL;DR

Pemafibrate (K-877) is the first selective PPARα modulator (SPPARMα), designed to retain the triglyceride-lowering and HDL-C-raising effects of fibrates while avoiding their off-target liver, kidney, and drug-interaction liabilities. This narrative review summarizes its pharmacology, preclinical data, and Japanese clinical trial program, and notes that the cardiovascular outcome trial PROMINENT is still ongoing.

Key findings

  • Pemafibrate's PPARα activation is >2500 times stronger than fenofibric acid, with subtype selectivity >5000-fold for PPARγ and >11,000-fold for PPARδ.
  • In clinical trials, pemafibrate 0.4 mg/day lowered TG by ~42.7% (vs 29.7% for fenofibrate 100 mg/day) and raised HDL-C by ~21.0% (vs 14.3%), with effects comparable to fenofibrate 200 mg/day; it reduced ALT, γ-GT, and ALP by ~8 U/L, ~24 U/L, and ~70–80 U/L respectively, whereas fenofibrate worsened these values.
  • Co-administered with pitavastatin, pemafibrate reduced fasting TG by 46.1% (0.1 mg/day), 53.4% (0.2 mg/day), and 52.0% (0.4 mg/day) versus 6.9% for placebo, with no major drug–drug interaction with statins.
  • Pemafibrate is mainly hepatically metabolized with only 14.5% urinary excretion and <0.5% unmetabolized drug in urine, so exposure does not increase with renal dysfunction; a meta-analysis found total adverse events significantly lower than with fenofibrate, though LDL-C was significantly higher in the pemafibrate group.

Methods

  • Narrative review synthesizing preclinical (cell, rodent, pig) and clinical data on pemafibrate, including its development, pharmacokinetics, and mechanism as a SPPARMα.
  • Draws on Japanese phase 2/3 randomized controlled trials (K-877-04, -09, -11, -17, -19), a meta-analysis comparing pemafibrate with fenofibrate, and animal models of dyslipidemia, atherosclerosis, NASH, and obesity.
  • Summarizes comparative tables of percentage changes in lipid, glycemic, liver, and renal parameters for pemafibrate versus fenofibrate.

Limitations

  • As stated by the paper: the cardiovascular benefit of pemafibrate in humans is not yet established—the large-scale PROMINENT trial (planned 10,000 patients with type 2 diabetes, high TG, low HDL-C, across 24 countries) is still ongoing.
  • As stated by the paper: pemafibrate was not administered to patients with extremely high TG (>1000 mg/dL) in developmental studies, and its effect in severe hypertriglyceridemia remains to be explored; the PBC evidence comes from a small pilot study.
  • Evident from the text: this is a narrative review without primary data or systematic search methodology, and much of the clinical evidence derives from Japanese trials, limiting generalizability to other populations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11883-020-0823-5

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Structural differences in the interaction of pemafibrate and fenofibrate with PPARα and the concept of SPPARMα. The binding affinity of pemafibrate to PPARα is markedly increased compared with that of fenofibrate because pemafibrate has many interaction sites in regions A, B, and C of PPARα. The specific binding of pemafibrate with a high affinity results in specific conformational transitions of PPARα, recruiting specific co-activator complexes. Thus, pemafibrate has specific effects on target genes, but not off-target genes. In contrast, fenofibrate has specific effects on target as well as off-target genes. Reproduced from ref [47••]. Partially modified from refs [43] and [48]
Fig. 1 Structural differences in the interaction of pemafibrate and fenofibrate with PPARα and the concept of SPPARMα. The binding affinity of pemafibrate to PPARα is markedly increased compared with that of fenofibrate because pemafibrate has many interaction sites in regions A, B, and C of PPARα. The specific binding of pemafibrate with a high affinity results in specific conformational transitions of PPARα, recruiting specific co-activator complexes. Thus, pemafibrate has specific effects on target genes, but not off-target genes. In contrast, fenofibrate has specific effects on target as well as off-target genes. Reproduced from ref [47••]. Partially modified from refs [43] and [48]CC BY · PubMed Central
Fig. 2 Molecular mechanisms for the favorable effects of pemafibrate on lipoprotein metabolism and reverse cholesterol transport. Abbreviations: ABCA1, ATP-binding cassette transporter A1; Angptl3, angiopoietin-like protein 3; LPL, lipoprotein lipase; Remnant-R, Remnant receptor; SR-BI, scavenger receptor class B type I; VLDL-R, VLDL receptor
Fig. 2 Molecular mechanisms for the favorable effects of pemafibrate on lipoprotein metabolism and reverse cholesterol transport. Abbreviations: ABCA1, ATP-binding cassette transporter A1; Angptl3, angiopoietin-like protein 3; LPL, lipoprotein lipase; Remnant-R, Remnant receptor; SR-BI, scavenger receptor class B type I; VLDL-R, VLDL receptorCC BY · PubMed Central
Fig. 3 Applications of SPPARMα, pemafibrate, to a variety of metabolic diseases Abbreviation: CKD, chronic kidney disease; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; RemL-C, remnant lipoprotein cholesterol; TG, triglycerides
Fig. 3 Applications of SPPARMα, pemafibrate, to a variety of metabolic diseases Abbreviation: CKD, chronic kidney disease; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; RemL-C, remnant lipoprotein cholesterol; TG, triglyceridesCC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 1 Not valid · 120 Not checked · 29 Own results and interpretations

86 more claims

Create a free account to see all 160 claims and to verify the 156 references still open.

See all claims — free account
  • It may state two separate claims as one. 67
  • Probably not a substantial claim. 5
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 124 references

Research works printed but not linked: 3

  1. Iwata H, Murakami K, Ricchiuto P, Singh S, Libby P, Aikawa E, et al. The novel PPARα selective agonist K-877 suppresses pro-inflammatory pathways and experimental arterial lesion formation. Circ Res. 2014;115:e86–93 (Abstract 24160).
  2. Iwata H, Murakami K, Ricchiuto P, Singh S, Libby P, Aikawa E, et al. The novel PPARα selective agonist K-877 suppresses pro-inflammatory pathways and experimental arterial lesion formation. Circ Res. 2014;115:e90 [AHA2014 Abstract].
  3. Takizawa T, Goto S, Inokuchi Y, Miyata S, Yoshinaka Y, Yamazaki H, et al. Pharmacological effects of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha)-Controlling the plasma HDL-C and triglycerides, and prevention of atherosclerosis in experimental animals. Eur Heart J. 2015;36:257–8 [ESC2015 Abstract].

Cited by

See all 192

Metadata

Authors
Yamashita, S., Masuda, D., & Matsuzawa, Y.
Affiliations
Rinku General Medical Center (JP)
Corresponding author
Yamashita, Shizuya
Venue
Current Atherosclerosis Reports
Published
2020-01
Volume
22
Issue
1
Pages
5-5
ISSN
  • 1523-3804 (ISSN-L)
  • 1534-6242
OpenAlex
W3002287592
Cited by
191
References
124
Citations by year
2026: 21 · 2025: 35 · 2024: 29 · 2023: 40 · 2022: 30 · 2021: 24 · 2020: 12
FWCI
2.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Atherosclerosis Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Kowa Company
  • Japan Society for the Promotion of Science (17H02100)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
pemafibrate, PPARα, hypertriglyceridemia, dyslipidemia, HDL cholesterol, LDL cholesterol, atherosclerotic cardiovascular disease, type 2 diabetes, drug-drug interactions, renal safety, liver safety, fibrates, statins, PCSK9 inhibitors, drug metabolism, drug repurposing
MeSH terms
Animals, Hypolipidemic Agents, Benzoxazoles, Butyrates, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Humans, Cholesterol, HDL, Fenofibrate, Triglycerides, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, PPAR alpha, Dyslipidemias, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. https://app.cochat.ai/papers/10.1007/s11883-020-0823-5
The paper
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020). Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-020-0823-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.